Accordingly, ex vivo-generated DC or tumor cells co-expressing transgene IL-15 and IL-15Rα, and engineered IL-15 agonists (e.g., IL-15/IL-15Rα-Fc complex, IL-15/IL-15Rα fusion protein) have been explored to generate effective antitumor responses.14,19-23,51. The gene discussed is IL15RA; the disease is neoplasm.